Patents Assigned to Mològen AG
-
Publication number: 20210079403Abstract: A TLR-9 agonist for use in the treatment of a tumor disease, in particular of colon cancer, and for the modulation of the tumor microenvironment.Type: ApplicationFiled: August 31, 2018Publication date: March 18, 2021Applicant: Mologen AGInventors: Manuel SCHMIDT, Kerstin KAPP
-
Publication number: 20210010003Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.Type: ApplicationFiled: February 18, 2020Publication date: January 14, 2021Applicant: Mologen AGInventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
-
Publication number: 20200385732Abstract: A TLR-9 agonist provided for use in treating small cell lung cancer (SCLC) in a subject in need thereof, wherein the subject to be treated has a low level of activated B cells and/or is diagnosed with chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: April 23, 2018Publication date: December 10, 2020Applicant: Mologen AGInventors: Manuel SCHMIDT, Kerstin KAPP, Maxim KRIKOV, Burghardt WITTIG
-
Publication number: 20200230234Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.Type: ApplicationFiled: September 21, 2016Publication date: July 23, 2020Applicant: MOLOGEN AGInventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO, Ole SCHMELTZ SOGAARD, Martin TOLSTRUP, Rasmus OFFERSEN
-
Patent number: 10604760Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.Type: GrantFiled: June 26, 2019Date of Patent: March 31, 2020Assignee: Mologen AGInventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
-
Patent number: 10487333Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.Type: GrantFiled: September 9, 2016Date of Patent: November 26, 2019Assignee: Mologen AGInventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
-
Publication number: 20190316134Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.Type: ApplicationFiled: June 26, 2019Publication date: October 17, 2019Applicant: Mologen AGInventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO
-
Patent number: 10280424Abstract: The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.Type: GrantFiled: February 18, 2015Date of Patent: May 7, 2019Assignee: Mologen AGInventors: Christiane Kleuss, Kerstin Kapp, Burghardt Wittig, Matthias Schroff
-
Publication number: 20180251767Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.Type: ApplicationFiled: September 9, 2016Publication date: September 6, 2018Applicant: MOLOGEN AGInventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO
-
Patent number: 10006032Abstract: The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.Type: GrantFiled: May 15, 2014Date of Patent: June 26, 2018Assignee: Mologen AGInventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Burghardt Wittig
-
Patent number: 9499815Abstract: The invention relates to a multimeric non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a preparation process therefore and a vaccine which comprises the multimeric non-coding nucleic acid molecule.Type: GrantFiled: May 11, 2007Date of Patent: November 22, 2016Assignee: Mologen AGInventors: Matthias Schroff, Burghardt Wittig, Manuel Schmidt, Janine Loehr
-
Patent number: 9375435Abstract: The present invention relates to the use of a DNA expression construct comprising a dumbbell-shaped circular strand of deoxyribonucleic acids and provides such a construct with a double-stranded stem and single-stranded loops located at both ends of the stem, wherein the stem comprises complementary deoxyribonucleic acids of the circular strand with a promotor sequence, a coding sequence and a termination signal to be administered by jet injection for the treatment of cancer.Type: GrantFiled: September 8, 2011Date of Patent: June 28, 2016Assignees: MOLOGEN AG, MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Wolfgang Walther, Peter M. Schlag, Dennis Kobelt, Manuel Schmidt
-
Patent number: 9345754Abstract: A vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of defined tumor diseases, and a method for the making of such vaccine is disclosed. The tumor cells were previously transfected ex vivo with expression constructs encoding cytokines and co-stimulatory factors.Type: GrantFiled: November 9, 2009Date of Patent: May 24, 2016Assignee: Mologen AGInventors: Tomislav Dobric, Burghardt Wittig, Manuel Schmidt
-
Patent number: 9212366Abstract: The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs.Type: GrantFiled: August 9, 2005Date of Patent: December 15, 2015Assignee: Mologen AGInventors: Burghardt Wittig, Manuel Schmidt, Heribert Bohlen
-
Publication number: 20150328308Abstract: A method of eliciting a cytotoxic immune response as a result of injecting antigen encoding expression constructs. Minimalistic expression constructs are used that comprise a promoter, a coding sequence and a terminator, and hairpin-shaped oligonucleotides on their ends, to the loop of which cationic peptides are covalently attached. These peptide-coupled expression constructs lead to a cell mediated response type after intradermal injection. The use of a DNA expression construct operable in eukaryotic cells for making a vaccine for intradermal injection to elicit a type 1 cell mediated immune mediated immune response is described.Type: ApplicationFiled: June 15, 2015Publication date: November 19, 2015Applicant: MOLOGEN AGInventors: Sonia Moreno-Lopez, Marcos Timon-Jimenez
-
Patent number: 9012620Abstract: The invention relates to expression constructs for targeted inhibition of gene expression and methods for their production and which, after transfection thereof into eukaryotic cells, are suitable for inhibiting in a targeted manner these cells formation of defined proteins by RNA interference, wherein the method is a three step method requiring no PCR steps and is carried out in one reaction vessel in a few hours and are suitable for multiple gene expression inhibition.Type: GrantFiled: November 22, 2006Date of Patent: April 21, 2015Assignee: Mologen AGInventors: Matthias Schroff, Detlef Oswald
-
Publication number: 20150050317Abstract: A means to elicit a cytotoxic immune response as a result of injecting antigen encoding expression constructs. Minimalistic expression constructs are used that comprise a promoter, a coding sequence and a terminator, and hairpin-shaped oligonucleotides on their ends, to the loop of which cationic peptides are covalently attached. These peptide-coupled expression constructs lead to a cell mediated response type after intradermal injection. The use of a DNA expression construct operable in eucaryotic cells for making a vaccine for intradermal injection to elicit a type 1 cell mediated immune mediated immune response is described.Type: ApplicationFiled: August 19, 2013Publication date: February 19, 2015Applicant: MOLOGEN AGInventors: Sonia Moreno-Lopez, Marcos Timon-Jimenez
-
Patent number: 8669100Abstract: The invention relates to using a combination of DNA-expression constructs for producing a drug for immunization against leishmania infections and a corresponding vaccine. The DNA-expression construct is also disclosed. According to said invention the immunogene P36 LACK is used in combination with a leishmania infantum thiol-specific antioxidant protein gene (TSA), leishmania infantum kinetoplastid membrane protein 11 (KMP-11) and with a leishmania infantum GP63 antigen for producing an immune response. Plasmides, preferably minimalist immunologically defined gene-expression constructs (MIDGE) can be used in the form of the DNA-expression construct. The inventive DNA-expression construct makes it possible to produce a vaccine for treating leishmania infectious diseases and is used in the form of a component of said vaccine.Type: GrantFiled: July 22, 2010Date of Patent: March 11, 2014Assignee: Mologen AGInventors: Burghardt Wittig, Laura Fuertes-López, Marcos Timón-Jiménez
-
Publication number: 20140010830Abstract: The present invention relates to a nucleic acid molecule and its use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising at least one nucleotide in L-conformation.Type: ApplicationFiled: December 23, 2011Publication date: January 9, 2014Applicant: MOLOGEN AGInventors: Matthias Schroff, Christiane Kleuss, Kerstin Kapp
-
Publication number: 20130273084Abstract: The present invention relates to the use of a DNA expression construct comprising a dumbbell-shaped circular strand of deoxyribonucleic acids and provides such a construct with a double-stranded stem and single-stranded loops located at both ends of the stem, wherein the stem comprises complementary deoxyribonucleic acids of the circular strand with a promotor sequence, a coding sequence and a termination signal to be administered by jet injection for the treatment of cancer.Type: ApplicationFiled: September 8, 2011Publication date: October 17, 2013Applicant: MOLOGEN AGInventors: Wolfgang Walther, Peter M. Schlag, Dennis Kobelt, Manuel Schmidt